Alexei Y Bagrov

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3786019/publications.pdf

Version: 2024-02-01

104 papers	4,855 citations	70961 41 h-index	98622 67 g-index
104 all docs	104 docs citations	104 times ranked	2260 citing authors

#	Article	IF	Citations
1	Canrenone Restores Vasorelaxation Impaired by Marinobufagenin in Human Preeclampsia. International Journal of Molecular Sciences, 2022, 23, 3336.	1.8	5
2	Effect of Cardiotonic Steroid Marinobufagenin on Vascular Remodeling and Cognitive Impairment in Young Dahl-S Rats. International Journal of Molecular Sciences, 2022, 23, 4563.	1.8	4
3	Chronic Î±1-Na/K-ATPase inhibition reverses the elongation of the axon initial segment of the hippocampal CA1 pyramidal neurons in Angelman syndrome model mice. Neuropsychopharmacology, 2021, 46, 654-664.	2.8	5
4	Model of Chronic Thromboembolic Pulmonary Hypertension in Rats Caused by Repeated Intravenous Administration of Partially Biodegradable Sodium Alginate Microspheres. International Journal of Molecular Sciences, 2021, 22, 1149.	1.8	7
5	Preeclampsia: Cardiotonic Steroids, Fibrosis, Fli1 and Hint to Carcinogenesis. International Journal of Molecular Sciences, 2021, 22, 1941.	1.8	8
6	High salt is a risk factor for cardiovascular and kidney diseases. What is next, fibrosis?. Journal of Hypertension, 2021, 39, 1309-1310.	0.3	1
7	Controlling the Movement of Magnetic Iron Oxide Nanoparticles Intended for Targeted Delivery of Cytostatics. International Journal of Nanomedicine, 2021, Volume 16, 5651-5664.	3.3	0
8	Endogenous Bufadienolide, Blood Pressure and Alcohol Withdrawal. Current Hypertension Reviews, 2021, 17, 170-173.	0.5	0
9	Antibody against Na/K-ATPase Inhibitor Lowers Blood Pressure and Increases Vascular Fli1 in Experimental Preeclampsia. American Journal of Hypertension, 2020, 33, 514-519.	1.0	5
10	Microvascular function in nonâ€dippers: Potential involvement of the salt sensitivity biomarker, marinobufageninâ€"The Africanâ€PREDICT study. Journal of Clinical Hypertension, 2020, 22, 86-94.	1.0	5
11	Î±1-Na/K-ATPase inhibition rescues aberrant dendritic calcium dynamics and memory deficits in the hippocampus of an Angelman syndrome mouse model. Progress in Neurobiology, 2019, 182, 101676.	2.8	9
12	Monoclonal Antibody to Marinobufagenin Downregulates TGFÎ² Profibrotic Signaling in Left Ventricle and Kidney and Reduces Tissue Remodeling in Saltâ€Sensitive Hypertension. Journal of the American Heart Association, 2019, 8, e012138.	1.6	15
13	Acute salt loading and cardiotonic steroids in resistant hypertension. Current Topics in Membranes, 2019, 83, 1-13.	0.5	3
14	Cardiotonic Steroids Induce Vascular Fibrosis Via Pressure-Independent Mechanism in NaCl-Loaded Diabetic Rats. Journal of Cardiovascular Pharmacology, 2019, 74, 436-442.	0.8	10
15	Endogenous Bufadienolides, Fibrosis and Preeclampsia. Cardiology Research and Practice, 2019, 2019, 1-7.	0.5	5
16	Large artery stiffness is associated with marinobufagenin in young adults. Journal of Hypertension, 2018, 36, 2333-2339.	0.3	15
17	Marinobufagenin in Urine: A Potential Marker of Predisposition to Ethanol and a Target for Spironolactone. Current Hypertension Reviews, 2018, 14, 35-38.	0.5	5
18	Dietary Sodium Restriction Reduces Arterial Stiffness, Vascular TGF-Î²-Dependent Fibrosis and Marinobufagenin in Young Normotensive Rats. International Journal of Molecular Sciences, 2018, 19, 3168.	1.8	27

#	Article	IF	Citations
19	Telocinobufagin, a Novel Cardiotonic Steroid, Promotes Renal Fibrosis via Na+/K+-ATPase Profibrotic Signaling Pathways. International Journal of Molecular Sciences, 2018, 19, 2566.	1.8	21
20	Antibody to Marinobufagenin Reverses Placenta-Induced Fibrosis of Umbilical Arteries in Preeclampsia. International Journal of Molecular Sciences, 2018, 19, 2377.	1.8	14
21	Selective ligands for Na+/K+-ATPase Î± isoforms differentially and cooperatively regulate excitability of pyramidal neurons in distinct brain regions. Neuropharmacology, 2017, 117, 338-351.	2.0	15
22	Comparison of Digitalis Sensitivities of Na⁺/K⁺-ATPases from Human and Pig Kidneys. ACS Omega, 2017, 2, 3610-3615.	1.6	15
23	The Pressure of Aging. Medical Clinics of North America, 2017, 101, 81-101.	1.1	32
24	Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Proâ€Fibrotic Signaling. Journal of the American Heart Association, 2016, 5, .	1.6	33
25	Aortic Fibrosis, Induced by High Salt Intake in the Absence of Hypertensive Response, Is Reduced by a Monoclonal Antibody to Marinobufagenin. American Journal of Hypertension, 2016, 29, 641-646.	1.0	22
26	Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists. Journal of Hypertension, 2015, 33, 1602-1610.	0.3	29
27	Plasma level of the endogenous sodium pump ligand marinobufagenin is related to the salt-sensitivity in men. Journal of Hypertension, 2015, 33, 534-541.	0.3	16
28	Synthesis of an Endogenous Steroidal Na Pump Inhibitor Marinobufagenin, Implicated in Human Cardiovascular Diseases, Is Initiated by CYP27A1 via Bile Acid Pathway. Circulation: Cardiovascular Genetics, 2015, 8, 736-745.	5.1	44
29	Elevated Plasma Marinobufagenin, An Endogenous Cardiotonic Steroid, Is Associated With Right Ventricular Dysfunction and Nitrative Stress in Heart Failure. Circulation: Heart Failure, 2015, 8, 1068-1076.	1.6	48
30	Magnesium Sulfate Potentiates Effect of Digifab on Marinobufagenin-Induced Na/K-ATPase Inhibition. American Journal of Hypertension, 2013, 26, 1269-1272.	1.0	5
31	Dietary Sodium Restriction and Association with Urinary Marinobufagenin, Blood Pressure, and Aortic Stiffness. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1952-1959.	2.2	63
32	Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure. American Journal of Hypertension, 2012, 25, 690-696.	1.0	82
33	High salt intake causes adverse fetal programming--vascular effects beyond blood pressure. Nephrology Dialysis Transplantation, 2012, 27, 3464-3476.	0.4	37
34	Age-associated increase in salt sensitivity is accompanied by a shift in the atrial natriuretic peptide modulation of the effect of marinobufagenin on renal and vascular sodium pump. Journal of Hypertension, 2012, 30, 1817-1826.	0.3	14
35	DigiFab Interacts With Endogenous Cardiotonic Steroids and Reverses Preeclampsia-Induced Na/K-ATPase Inhibition. Reproductive Sciences, 2012, 19, 1260-1267.	1.1	15
36	In preeclampsia endogenous cardiotonic steroids induce vascular fibrosis and impair relaxation of umbilical arteries. Journal of Hypertension, 2011, 29, 769-776.	0.3	39

#	Article	IF	Citations
37	Endogenous cardiotonic steroids in chronic renal failure. Nephrology Dialysis Transplantation, 2011, 26, 2912-2919.	0.4	68
38	Interaction of Digibind with endogenous cardiotonic steroids from preeclamptic placentae. Journal of Hypertension, 2010, 28, 361-366.	0.3	25
39	Renal Ischemia Regulates Marinobufagenin Release in Humans. Hypertension, 2010, 56, 914-919.	1.3	38
40	Endogenous cardiotonic steroids and salt-sensitive hypertension. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 1230-1236.	1.8	68
41	Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets. Pharmacological Reviews, 2009, 61, 9-38.	7.1	475
42	Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy. American Journal of Physiology - Renal Physiology, 2009, 296, F1219-F1226.	1.3	84
43	Marinobufagenin enhances cardiac contractility in mice with ouabain-sensitive Î±₁Na⁺-K⁺-ATPase. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H1833-H1839.	1.5	31
44	The cardiotonic steroid hormone marinobufagenin induces renal fibrosis: implication of epithelial-to-mesenchymal transition. American Journal of Physiology - Renal Physiology, 2009, 296, F922-F934.	1.3	61
45	Endogenous Cardiotonic Steroids and Differential Patterns of Sodium Pump Inhibition in NaCl-Loaded Salt-Sensitive and Normotensive Rats. American Journal of Hypertension, 2009, 22, 559-563.	1.0	30
46	Spironolactone Attenuates Experimental Uremic Cardiomyopathy by Antagonizing Marinobufagenin. Hypertension, 2009, 54, 1313-1320.	1.3	84
47	Endogenous bufadienolide mediates pressor response to ethanol withdrawal in rats. European Neuropsychopharmacology, 2008, 18, 74-77.	0.3	7
48	Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. Journal of Hypertension, 2008, 26, 2414-2425.	0.3	73
49	Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. American Journal of Physiology - Renal Physiology, 2008, 294, F450-F454.	1.3	96
50	Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 294, R1248-R1254.	0.9	54
51	Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nature Clinical Practice Nephrology, 2008, 4, 378-392.	2.0	103
52	Marinobufagenin Stimulates Fibroblast Collagen Production and Causes Fibrosis in Experimental Uremic Cardiomyopathy. Hypertension, 2007, 49, 215-224.	1.3	145
53	Intrahippocampal microinjection of an exquisitely low dose of ouabain mimics NaCl loading and stimulates a bufadienolide Na/K-ATPase inhibitor. Journal of Hypertension, 2007, 25, 1834-1844.	0.3	32
54	Endogenous sodium pump inhibitors, diabetes mellitus and preeclampsia. Pathophysiology, 2007, 14, 147-151.	1.0	11

#	Article	IF	Citations
55	Cardiotonic Steroids Stimulate Glycogen Synthesis in Human Skeletal Muscle Cells via a Src- and ERK1/2-dependent Mechanism. Journal of Biological Chemistry, 2006, 281, 20085-20094.	1.6	61
56	Central Role for the Cardiotonic Steroid Marinobufagenin in the Pathogenesis of Experimental Uremic Cardiomyopathy. Hypertension, 2006, 47, 488-495.	1.3	246
57	ANP Differentially Modulates Marinobufagenin-Induced Sodium Pump Inhibition in Kidney and Aorta. Hypertension, 2006, 48, 1160-1168.	1.3	34
58	Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake. Journal of Hypertension, 2005, 23, 835-842.	0.3	79
59	Brain ouabain stimulates peripheral marinobufagenin via angiotensin II signalling in NaCl-loaded Dahl-S rats. Journal of Hypertension, 2005, 23, 1515-1523.	0.3	79
60	Salt loading induces redistribution of the plasmalemmal Na/K-ATPase in proximal tubule cells. Kidney International, 2005, 67, 1868-1877.	2.6	69
61	Cardenolide and bufadienolide ligands of the sodium pump. how they work together in NaCl sensitive hypertension. Frontiers in Bioscience - Landmark, 2005, 10, 2250.	3.0	32
62	Endogenous digitalis-like ligands and Na/K-ATPase inhibition in experimental diabetes mellitus. Frontiers in Bioscience - Landmark, 2005, 10, 2257.	3.0	33
63	Cardiotonic Steroids Differentially Affect Intracellular Na+ and [Na+] /[K+] -independent Signaling in C7-MDCK Cells. Journal of Biological Chemistry, 2005, 280, 832-839.	1.6	64
64	Involvement of Marinobufagenin in a Rat Model of Human Preeclampsia. American Journal of Nephrology, 2005, 25, 520-528.	1.4	81
65	The Dietary Sodium-Blood Pressure Plot â€œStiffensâ€: Hypertension, 2004, 44, 22-24.	1.3	36
66	Coordinated shifts in Na/K-ATPase isoforms and their endogenous ligands during cardiac hypertrophy and failure in NaCl-sensitive hypertension. Journal of Hypertension, 2004, 22, 389-397.	0.3	32
67	Effect of green tea extract on cardiac hypertrophy following 5/6 nephrectomy in the rat. Kidney International, 2003, 63, 1785-1790.	2.6	64
68	Myocardial PKC Î²2 and the Sensitivity of Na/K-ATPase to Marinobufagenin Are Reduced by Cicletanine in Dahl Hypertension. Hypertension, 2003, 41, 505-511.	1.3	25
69	Phorbol Diacetate Potentiates Na + -K + ATPase Inhibition by a Putative Endogenous Ligand, Marinobufagenin. Hypertension, 2002, 39, 298-302.	1.3	23
70	Endogenous Ligand of Î± 1 Sodium Pump, Marinobufagenin, Is a Novel Mediator of Sodium Chlorideâ€“Dependent Hypertension. Circulation, 2002, 105, 1122-1127.	1.6	155
71	Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity. Journal of Hypertension, 2002, 20, 1189-1194.	0.3	66
72	Endogenous digitalis-like ligands of the sodium pump: possible involvement in mood control and ethanol addiction. European Neuropsychopharmacology, 2002, 12, 1-12.	0.3	23

#	Article	IF	Citations
73	Marinobufagenin (MBG) suppression of ethanol-seeking behavior is associated with inhibition of brain cortex Na/K-ATPase in mice. European Neuropsychopharmacology, 2002, 12, 217-223.	0.3	12
74	Effects of cardiac glycosides on sodium pump expression and function in LLC-PK1 and MDCK cells. Kidney International, 2002, 62, 2118-2125.	2.6	66
75	Racial differences in resting end-tidal CO2 and circulating sodium pump inhibitor. American Journal of Hypertension, 2001, 14, 761-767.	1.0	11
76	Interaction of NaCl and behavioral stress on endogenous sodium pump ligands in rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 281, R352-R358.	0.9	31
77	Effects of uremic serum on isolated cardiac myocyte calcium cycling and contractile function.. Kidney International, 2001, 60, 2367-2376.	2.6	43
78	Marinobufagenin, an Endogenous Î±-1 Sodium Pump Ligand, in Hypertensive Dahl Salt-Sensitive Rats. Hypertension, 2001, 37, 462-466.	1.3	102
79	Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism. Journal of Hypertension, 2000, 18, 209-215.	0.3	17
80	Endogenous Na,K Pump Ligands Are Differentially Regulated During Acute NaCl Loading of Dahl Rats. Circulation, 2000, 102, 3009-3014.	1.6	120
81	Mammalian Bufadienolide Is Synthesized From Cholesterol in the Adrenal Cortex by a Pathway That Is Independent of Cholesterol Side-Chain Cleavage. Hypertension, 2000, 36, 442-448.	1.3	67
82	Involvement of endogenous digitalis-like factors involuntary selection of alcohol by rats. Life Sciences, 1999, 64, PL219-PL225.	2.0	15
83	Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. Journal of Hypertension, 1999, 17, 1179-1187.	0.3	162
84	Vasorelaxant effects of cicletanine and its (+)- and (â˜)-enantiomers in isolated human pulmonary arteries. American Journal of Hypertension, 1998, 11, 1386-1389.	1.0	1
85	Endogenous Sodium Pump Inhibitors and Blood Pressure Regulation: An Update on Recent Progress. Experimental Biology and Medicine, 1998, 218, 156-167.	1.1	43
86	Plasma Marinobufagenin-Like and Ouabain-Like Immunoreactivity in Adrenocorticotropin-Treated Rats. American Journal of Hypertension, 1998, 11, 796-802.	1.0	26
87	Characterization of a Urinary Bufodienolide Na+,K+-ATPase Inhibitor in Patients After Acute Myocardial Infarction. Hypertension, 1998, 31, 1097-1103.	1.3	157
88	Sodium sensitivity in young adults with high resting end-tidal CO2. Journal of Hypertension, 1998, 16, 1015-1022.	0.3	11
89	Effects of two putative endogenous digitalis-like factors, marinobufagenin and ouabain, on the Na+,K+-pump in human mesenteric arteries. Journal of Hypertension, 1998, 16, 1953-1958.	0.3	65
90	Inhibition of Na/K ATPase From Rat Aorta by Two Na/K Pump Inhibitors, Ouabain and Marinobufagenin Evidence of Interaction With Different Î±-Subunit Isoforms. American Journal of Hypertension, 1997, 10, 929-935.	1.0	87

#	Article	IF	Citations
91	Endogenous marinobufagenin-like immunoreactive substance*A possible endogenous Na,K-ATPase inhibitor with vasoconstrictor activity. American Journal of Hypertension, 1996, 9, 982-990.	1.0	43
92	High end tidal CO2association with blood pressure response to sodium loading in older adults. Journal of Hypertension, 1996, 14, 1073-1079.	0.3	22
93	Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs. Cardiovascular Research, 1996, 31, 296-305.	1.8	64
94	Inhibited Breathing Decreases Renal Sodium Excretion. Psychosomatic Medicine, 1995, 57, 373-380.	1.3	21
95	Effects of two endogenous Na+,K+-ATPase inhibitors, marinobufagenin and ouabain, on isolated rat aorta. European Journal of Pharmacology, 1995, 274, 151-158.	1.7	72
96	Endogenous Marinobufagenin-like Immunoreactive Factor and Na + ,K + ATPase Inhibition During Voluntary Hypoventilation. Hypertension, 1995, 26, 781-788.	1.3	84
97	Endogenous digoxinâ€like factor in acute myocardial infarction. Journal of Internal Medicine, 1994, 235, 63-67.	2.7	25
98	Plasma Î²-endorphin levels in acute myocardial infarction. Annals of Emergency Medicine, 1993, 22, 268-269.	0.3	4
99	Digitalis-like and vasoconstrictor effects of endogenous digoxin-like factor(s) from the venom of Bufo marinus toad. European Journal of Pharmacology, 1993, 234, 165-172.	1.7	62
100	Effect of endogenous digoxin-like factor and digoxin antibody on myocardial Na+, K+-pump activity and ventricular arrhythmias in acute myocardial ischaemia in rats. Cardiovascular Research, 1993, 27, 1045-1050.	1.8	17
101	Endogenous Digoxin-Like Factor: Possible Emergency Implications. Prehospital and Disaster Medicine, 1992, 7, 65-68.	0.7	0
102	Gangliosides protect erythrocyte membranes from myocardial ischemia. Bulletin of Experimental Biology and Medicine, 1992, 114, 1436-1439.	0.3	1
103	Antiarrhythmic effect of antibodies to digoxin in experimental myocardial infarction (the) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Medicine, 1991, 112, 919-921.	0.3	1
104	Endogenous plasma Na,K-ATPase inhibitory activity and digoxin like immunoreactivity after acute myocardial infarction. Cardiovascular Research, 1991, 25, 371-377.	1.8	43